178 related articles for article (PubMed ID: 35601881)
1. Efficacy of clofazimine and nitazoxanide combination in treating intestinal cryptosporidiosis and enhancing intestinal cellular regeneration in immunocompromised mice.
Esmat M; Abdel-Aal AA; Shalaby MA; Badawi M; Elaskary H; Yousif AB; Fahmy MA
Food Waterborne Parasitol; 2022 Jun; 27():e00161. PubMed ID: 35601881
[No Abstract] [Full Text] [Related]
2. Evaluating the safety, tolerability, pharmacokinetics and efficacy of clofazimine in cryptosporidiosis (CRYPTOFAZ): study protocol for a randomized controlled trial.
Nachipo P; Hermann D; Quinnan G; Gordon MA; Van Voorhis WC; Iroh Tam PY
Trials; 2018 Aug; 19(1):456. PubMed ID: 30139372
[TBL] [Abstract][Full Text] [Related]
3.
Gattan HS; Wakid MH; Qahwaji RM; Altwaim S; Mahjoub HA; Alfaifi MS; Elshazly H; Al-Megrin WAI; Alshehri EA; Elshabrawy HA; El-Kady AM
Front Vet Sci; 2024; 11():1374116. PubMed ID: 38515537
[TBL] [Abstract][Full Text] [Related]
4. Octaarginine Improves the Efficacy of Nitazoxanide against
Nguyen-Ho-Bao T; Ambe LA; Berberich M; Hermosilla C; Taubert A; Daugschies A; Kamena F
Pathogens; 2022 Jun; 11(6):. PubMed ID: 35745507
[TBL] [Abstract][Full Text] [Related]
5. A high-throughput phenotypic screen identifies clofazimine as a potential treatment for cryptosporidiosis.
Love MS; Beasley FC; Jumani RS; Wright TM; Chatterjee AK; Huston CD; Schultz PG; McNamara CW
PLoS Negl Trop Dis; 2017 Feb; 11(2):e0005373. PubMed ID: 28158186
[TBL] [Abstract][Full Text] [Related]
6. The immunomodulatory activity of secnidazole-nitazoxanide in a murine cryptosporidiosis model.
Madbouly N; El Amir A; Abdel Kader A; Rabee I; Farid A
J Med Microbiol; 2021 Mar; 70(3):. PubMed ID: 33625354
[No Abstract] [Full Text] [Related]
7. Pyroptosis Tuning in Intestinal Cryptosporidiosis via the Natural Histone Deacetylase Inhibitor Romidepsin.
Shalaby NE; Shoheib ZS; Yassin NA; El-Kaliny HH; Hasby Saad MA
Parasite Immunol; 2024 Mar; 46(3):e13032. PubMed ID: 38497997
[TBL] [Abstract][Full Text] [Related]
8. Assessment of Cryptosporidium parvum infection in immunocompetent and immunocompromised mice and its role in triggering intestinal dysplasia.
Abdou AG; Harba NM; Afifi AF; Elnaidany NF
Int J Infect Dis; 2013 Aug; 17(8):e593-600. PubMed ID: 23291034
[TBL] [Abstract][Full Text] [Related]
9. Eugenol: effective complementary treatment for cryptosporidiosis in experimentally infected mice.
Gattan HS; Fouad SS; Ellisy RA; Elshazly H; El-Kady AM
J Parasit Dis; 2024 Jun; 48(2):370-380. PubMed ID: 38840881
[TBL] [Abstract][Full Text] [Related]
10. Apoptotic changes in the intestinal epithelium of
Hassan ZR; Salama DEA; Ibrahim HF
J Parasit Dis; 2022 Dec; 46(4):1011-1020. PubMed ID: 36457780
[No Abstract] [Full Text] [Related]
11. Pharmacokinetics and Pharmacodynamics of Clofazimine for Treatment of Cryptosporidiosis.
Zhang CX; Love MS; McNamara CW; Chi V; Woods AK; Joseph S; Schaefer DA; Betzer DP; Riggs MW; Iroh Tam PY; Van Voorhis WC; Arnold SLM
Antimicrob Agents Chemother; 2022 Jan; 66(1):e0156021. PubMed ID: 34748385
[TBL] [Abstract][Full Text] [Related]
12. Antiparasitic and immunomodulating effects of nitazoxanide, ivermectin and selenium on Cryptosporidium infection in diabetic mice.
Fahmy MA; Abdelaal AA; Hassan SI; Shalaby MA; Ismail MAM; Khairy RA; Badawi MA; Afife AA; Fadl HO
Rev Bras Parasitol Vet; 2021; 30(4):e012121. PubMed ID: 34852131
[TBL] [Abstract][Full Text] [Related]
13. Clofazimine for Treatment of Cryptosporidiosis in Human Immunodeficiency Virus Infected Adults: An Experimental Medicine, Randomized, Double-blind, Placebo-controlled Phase 2a Trial.
Iroh Tam P; Arnold SLM; Barrett LK; Chen CR; Conrad TM; Douglas E; Gordon MA; Hebert D; Henrion M; Hermann D; Hollingsworth B; Houpt E; Jere KC; Lindblad R; Love MS; Makhaza L; McNamara CW; Nedi W; Nyirenda J; Operario DJ; Phulusa J; Quinnan GV; Sawyer LA; Thole H; Toto N; Winter A; Van Voorhis WC
Clin Infect Dis; 2021 Jul; 73(2):183-191. PubMed ID: 32277809
[TBL] [Abstract][Full Text] [Related]
14. The Effects of Commercially Available
Gaber M; Galal LAA; Farrag HMM; Badary DM; Alkhalil SS; Elossily N
Infect Drug Resist; 2022; 15():171-182. PubMed ID: 35087280
[TBL] [Abstract][Full Text] [Related]
15.
El-Wakil ES; Abdelmaksoud HF; Wakid MH; Alsulami MN; Hammam O; Albohiri HH; Ghallab MMI
Pharmaceuticals (Basel); 2023 Jun; 16(6):. PubMed ID: 37375825
[TBL] [Abstract][Full Text] [Related]
16. Assessment of chitosan nanoparticles in improving the efficacy of nitazoxanide on cryptosporidiosis in immunosuppressed and immunocompetent murine models.
Moawad HSF; Hegab MHAE; Badawey MSR; Ashoush SE; Ibrahim SM; Ali AAES
J Parasit Dis; 2021 Sep; 45(3):606-619. PubMed ID: 34475640
[TBL] [Abstract][Full Text] [Related]
17. The controverted therapeutic efficacy of Allium sativum and Artemisia herba-alba extracts on Cryptosporidium-infected mice.
Elbahaie ES; El Gamal RL; Fathy GM; Al-Ghandour AMF; El-Akabawy N; Abd El Hameed BH; Yahia SH
J Infect Dev Ctries; 2023 Jun; 17(6):732-743. PubMed ID: 37406057
[TBL] [Abstract][Full Text] [Related]
18. Novel treatment strategies and drugs in development for cryptosporidiosis.
Chavez MA; White AC
Expert Rev Anti Infect Ther; 2018 Aug; 16(8):655-661. PubMed ID: 30003818
[TBL] [Abstract][Full Text] [Related]
19. Nitazoxanide, Ivermectin, and Artemether effects against cryptosporidiosis in diabetic mice: parasitological, histopathological, and chemical studies.
El-Ashkar AM; Mahmoud S; Sabry H; Guirguis N; El Komi W; Ali E; Abu Shousha T; Abdelmksoud HF
J Parasit Dis; 2022 Dec; 46(4):1070-1079. PubMed ID: 36092469
[TBL] [Abstract][Full Text] [Related]
20. Intestinal cryptosporidiosis: pathophysiologic alterations and specific cellular and humoral immune responses in rnu/+ and rnu/rnu (athymic) rats.
Gardner AL; Roche JK; Weikel CS; Guerrant RL
Am J Trop Med Hyg; 1991 Jan; 44(1):49-62. PubMed ID: 1996741
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
